Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04201158
Other study ID # GO19/60
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 15, 2019
Est. completion date April 1, 2020

Study information

Verified date May 2020
Source Hacettepe University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

It is known that activities of daily living, physical fitness, exercise capacity and quality of life are affected by the obesity. It is aimed to determine the effects obesity on daily living activities, physical fitness, exercise capacity and quality of life in obese adolescents compared to healthy subjects in this study. The relationship between these parameters and the activities of daily living which are less studied in obese adolescents will be evaluated.


Description:

Obesity among children, adolescents and adults has emerged as one of the most serious public health problems in the 21st century. There has been a significant decrease in the exercise capacity, physical fitness and activities of daily living of children and adolescents with the increase in the prevalence of obesity over the last decade. Obesity can cause not only health problems but also psychological effects. This situation have negative effects on the quality of life. The effect of these parameters on healthy individuals and obese adolescents will be demonstrated by this study and will guide the rehabilitation of obese adolescents.


Recruitment information / eligibility

Status Completed
Enrollment 32
Est. completion date April 1, 2020
Est. primary completion date April 1, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 10 Years to 18 Years
Eligibility Inclusion Criteria:

Healthy group:

- Being normal weight according to BMI reference system,

- Being between the ages of 10-18 and volunteer to participate in the research,

- Being able to walk and cooperate

Obese Group:

- Obesity diagnosis according to BMI reference system,

- Being between the ages of 10-18 and volunteer to participate in the research,

- Being able to walk and cooperate.

Exclusion Criteria:

Healthy Group:

- Comorbidities that may affect exercise performance and other physical tests,

- Having cardiovascular problems, musculoskeletal and neurological disease,

- Having cognitive or motor limitation or other chronic diseases.

Obese Group:

- Having a neurological disease or other clinical diagnosis that may affect cognitive status,

- Having musculoskeletal and neurological diseases, symptomatic heart disease, lung disease, diabetes, hypertension and malignant disease that may affect exercise performance,

- Using medication that affects appetite and weight.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Exercise Capacity
Modified Shuttle Walk Test

Locations

Country Name City State
Turkey Hacettepe University Ankara Samanpazari

Sponsors (1)

Lead Sponsor Collaborator
Hacettepe University

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary The Modified shuttle walk test. Maximal exercise capacity February 2019-February 2020
Secondary Waist circumference, Abdominal circumference, Ratio of waist to hip Antropometric measurements February 2019-February 2020
Secondary Hand grip strength by hand dynamometer (Jamar). Peripheral Muscle Strength February 2019-February 2020
Secondary the Glittre Activities of Daily Living (ADL) Test. Activities of daily living February 2019-February 2020
Secondary the Munich Physical Fitness Test-MFT Physical Fitness February 2019-February 2020
Secondary Modified push-ups, shuttles and squats as possible for 30 seconds Peripheral muscle endurance February 2019-February 2020
Secondary The Pediatric Outcomes Data Collection Instrument (PODCI) Quality of Life February 2019-February 2020
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1